Scholarlink

Introduction <p>Concomitant liver biopsy during bariatric surgery has gained interest for diagnostic and research purposes, particularly in studying obesity-related liver disease. However, comprehensive data on safety remains limited using recent national databases.</p> Methods <p>A retrospective analysis of the MBSAQIP database from 2020 to 2022 was conducted. Patients undergoing primary Roux-en-Y gastric bypass or sleeve gastrectomy with or without concomitant liver biopsy were included. Primary outcomes were 30-day major complications (Clavien-Dindo grade III and IV) and mortality. Separate multivariable analyses were performed for bleeding-related complications including postoperative bleeding, transfusion requirements, and reoperation. Multivariable logistic regression analysis determined if concomitant liver biopsy independently predicted adverse outcomes.</p> Results <p>Of 511,981 patients, 30,819 (6.02%) underwent concomitant liver biopsy. Biopsy patients had higher rates of diabetes (28.25% vs 22.65%, <i>p</i> &lt; 0.001) and hyperlipidemia (25.20% vs 22.14%, <i>p</i> &lt; 0.001). Mean operative time was longer in the biopsy group (96.10 vs 83.59 min, <i>p</i> &lt; 0.001). Unadjusted analysis showed higher rates of major complications (Clavien-Dindo grade III and IV) (3.15% vs 2.70%, <i>p</i> &lt; 0.001) and 30-day readmission (3.32% vs 2.86%, <i>p</i> &lt; 0.001) in the biopsy group. However, on multivariable analysis, concomitant liver biopsy was not independently predictive of major complications (OR 0.91, 95%CI 0.79–1.04, <i>p</i> = 0.164) or 30-day readmission (OR 1.06, 95%CI 0.94–1.21, <i>p</i> = 0.344). Separate multivariable analyses for bleeding-related complications revealed that concomitant liver biopsy was independently associated with increased postoperative bleeding (OR 1.203, 95%CI 1.018–1.422, <i>p</i> = 0.030) and transfusion requirements (OR 1.171, 95%CI 1.028–1.334, <i>p</i> = 0.018), but not with reoperation (OR 1.016, 95%CI 0.908–1.138, <i>p</i> = 0.783).</p> Conclusion <p>After adjusting for patient factors, concomitant liver biopsy during bariatric surgery does not independently increase the risk of major complications (Clavien-Dindo grade III and IV), readmission, or mortality. However, it is associated with increased bleeding and transfusion complications. These findings support that liver biopsy can be performed during bariatric surgery, though clinicians should be prepared for increased bleeding-related risks and blood product utilization.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Concomitant Liver Biopsy During Bariatric Surgery: No Increase in Major Complications or Readmissions but Associated with Higher Transfusion Requirements - An Analysis of the MBSAQIP Database

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月25日

查看全文
  • Juan S. Barajas-Gamboa,
  • Kayanne Khoury,
  • Valentin Mocanu,
  • Mélissa V. Wills,
  • Thomas H. Shin,
  • Gustavo Romero-Velez,
  • Matthew Allemang,
  • Andrew T. Strong,
  • Salvador Navarrete,
  • Ricard Corcelles,
  • A. Daniel Guerron,
  • John Rodriguez,
  • Matthew Kroh,
  • Jerry T. Dang

摘要

Introduction

Concomitant liver biopsy during bariatric surgery has gained interest for diagnostic and research purposes, particularly in studying obesity-related liver disease. However, comprehensive data on safety remains limited using recent national databases.

Methods

A retrospective analysis of the MBSAQIP database from 2020 to 2022 was conducted. Patients undergoing primary Roux-en-Y gastric bypass or sleeve gastrectomy with or without concomitant liver biopsy were included. Primary outcomes were 30-day major complications (Clavien-Dindo grade III and IV) and mortality. Separate multivariable analyses were performed for bleeding-related complications including postoperative bleeding, transfusion requirements, and reoperation. Multivariable logistic regression analysis determined if concomitant liver biopsy independently predicted adverse outcomes.

Results

Of 511,981 patients, 30,819 (6.02%) underwent concomitant liver biopsy. Biopsy patients had higher rates of diabetes (28.25% vs 22.65%, p < 0.001) and hyperlipidemia (25.20% vs 22.14%, p < 0.001). Mean operative time was longer in the biopsy group (96.10 vs 83.59 min, p < 0.001). Unadjusted analysis showed higher rates of major complications (Clavien-Dindo grade III and IV) (3.15% vs 2.70%, p < 0.001) and 30-day readmission (3.32% vs 2.86%, p < 0.001) in the biopsy group. However, on multivariable analysis, concomitant liver biopsy was not independently predictive of major complications (OR 0.91, 95%CI 0.79–1.04, p = 0.164) or 30-day readmission (OR 1.06, 95%CI 0.94–1.21, p = 0.344). Separate multivariable analyses for bleeding-related complications revealed that concomitant liver biopsy was independently associated with increased postoperative bleeding (OR 1.203, 95%CI 1.018–1.422, p = 0.030) and transfusion requirements (OR 1.171, 95%CI 1.028–1.334, p = 0.018), but not with reoperation (OR 1.016, 95%CI 0.908–1.138, p = 0.783).

Conclusion

After adjusting for patient factors, concomitant liver biopsy during bariatric surgery does not independently increase the risk of major complications (Clavien-Dindo grade III and IV), readmission, or mortality. However, it is associated with increased bleeding and transfusion complications. These findings support that liver biopsy can be performed during bariatric surgery, though clinicians should be prepared for increased bleeding-related risks and blood product utilization.